Professor Richard Scolyer, one of Australia's most prominent cancer researchers and a former Australian of the Year, has died at the age of 59. The Guardian reported his death following a diagnosis of inoperable brain cancer in 2023.
A Career Built on Melanoma and Immunotherapy
Scolyer was widely recognised as an eminent pathologist whose career centred on melanoma — a field in which he made substantial contributions over several decades. His research extended into immunotherapy, an area of oncology that has reshaped how certain cancers are treated. The work he undertook helped advance understanding of how the immune system can be directed against tumour cells, a line of inquiry that has since informed clinical practice internationally.
His standing in the scientific community was reflected in his recognition as Australian of the Year, an honour that brought broader public attention to the field of cancer research and to the particular challenges posed by melanoma, which remains a significant cause of cancer-related mortality in Australia.
Diagnosis and Final Months
In 2023, Scolyer received a diagnosis of inoperable brain cancer. According to The Guardian, he continued to engage with his work and with public communication about his condition in the period that followed. Before his illness reached its final stages, he prepared a written statement, which his family subsequently shared publicly — a gesture consistent with the openness he had brought to discussing his diagnosis from the outset.
The circumstances of his illness drew particular attention given his professional background. As a researcher who had spent his career studying cancer biology and treatment, Scolyer approached his own diagnosis with a degree of scientific transparency that was noted by colleagues and commentators alike.
Significance for Cancer Research
Scolyer's contributions to melanoma pathology spanned both laboratory research and clinical application. Melanoma, while representing a smaller proportion of skin cancer cases overall, accounts for a disproportionate share of skin cancer deaths, and advances in its treatment have depended heavily on improvements in both early detection and systemic therapy. Immunotherapy has been central to those improvements, and Scolyer's work intersected directly with that progress.
His death at 59 marks the loss of a researcher who remained active in the field until late in his illness. Tributes from within the scientific and medical communities reflected the breadth of his influence, both within Australia and in international cancer research circles.
The Guardian's report noted that his family released the statement he had written, underscoring the deliberate and considered way in which he had approached the final chapter of his life — consistent, those who knew him suggested, with the rigour he brought to his scientific work.